Peptide Stability and Degradation Pathways Explained

Peptides are chemically more delicate than most small-molecule reagents. Their backbones can be cut, their side chains modified and their molecules pushed into aggregates, all without any visible change to the vial. Knowing the main degradation pathways explains the standard storage advice and helps you interpret unexpected results.

Two families of instability

Degradation is usually grouped into two categories:

• Chemical instability: covalent bonds are made or broken, producing a new chemical species. Examples are oxidation, deamidation, hydrolysis and disulfide scrambling.
• Physical instability: the covalent structure is unchanged, but the molecules change their conformation or association. Examples are aggregation, adsorption to surfaces and precipitation.

Both can reduce the amount of active, correctly structured peptide in a sample. Chemical changes are usually visible by HPLC and mass spectrometry; physical changes may need other techniques such as size-exclusion chromatography or light scattering.

The main chemical pathways

Pathway	Residues most affected	Mass change	Main accelerating factors
Oxidation	Met, Cys, Trp, His, Tyr	+16 Da per oxygen (Met sulfoxide)	Dissolved oxygen, peroxides, trace metals, light
Deamidation	Asn (especially Asn-Gly), Gln	+1 Da	Neutral to basic pH, temperature, flexible sequences
Hydrolysis	Asp-Pro, Asp-Gly bonds	Fragmentation	Acidic pH, temperature, water
Disulfide exchange	Cys	0 Da (scrambled)	Basic pH, free thiols
Pyroglutamate formation	N-terminal Gln or Glu	−17 or −18 Da	Temperature, acidic conditions
Diketopiperazine formation	N-terminal dipeptides with Pro or Gly	Loss of two residues	Neutral pH, temperature

Oxidation

Methionine is the residue most readily oxidised, forming methionine sulfoxide (+16 Da) and, under harsher conditions, the sulfone (+32 Da). Cysteine can form disulfides or more highly oxidised species. Tryptophan oxidises to a range of products, some of them coloured, which is one reason degraded samples can turn yellow.

Oxidation is driven by dissolved oxygen, peroxide impurities in solvents or excipients, trace metal ions (iron and copper catalyse radical reactions) and light. Copper-binding peptides such as GHK-Cu, and thiol-containing molecules such as glutathione, are naturally sensitive to redox conditions and benefit from careful handling.

Deamidation

Asparagine and glutamine side chains can lose ammonia to form a cyclic intermediate (a succinimide), which then hydrolyses to aspartic acid or iso-aspartic acid. The net mass change is only about +1 Da, so it can be missed at low resolution, but it changes the charge of the peptide and often its HPLC retention time.

The rate depends strongly on the neighbouring residue. Asparagine followed by glycine (Asn-Gly) is the classic hot spot; under physiological conditions its half-life can be on the order of a day in short peptides. Robinson and Robinson catalogued these sequence effects extensively and proposed that deamidation acts as a molecular clock in biology.

Hydrolysis and aspartate chemistry

The peptide backbone is thermodynamically unstable toward hydrolysis but usually kinetically slow. Bonds next to aspartic acid are the exception, particularly Asp-Pro and Asp-Gly. Aspartate can also cyclise to a succinimide and reopen as iso-aspartate, a structural isomer with identical mass that typically elutes near the parent peak.

Physical instability: aggregation

Aggregation is the self-association of peptide molecules into dimers, oligomers, amorphous clumps or ordered fibrils. Hydrophobic and amphipathic sequences, high concentration, pH near the isoelectric point, agitation and air–water interfaces all increase the risk.

Aggregation matters for several reasons:

• It reduces the concentration of monomeric, active peptide.
• Some aggregates are irreversible and will not redissolve.
• Aggregates can behave differently in biological assays from the monomer.

Lipidated peptides such as semaglutide self-associate in solution by design, and their behaviour depends on concentration and formulation. For research purposes, a cloudy solution, visible particles or a gel are signs that aggregation or precipitation has occurred.

Adsorption to surfaces is a related problem. At low concentrations, a significant fraction of a hydrophobic peptide can stick to glass or plastic. Low-binding tubes, carrier proteins where appropriate, or a small proportion of organic solvent can reduce losses.

Environmental factors

Temperature

Most degradation reactions speed up with temperature. As a rough rule of thumb from the Arrhenius relationship, many reaction rates increase two- to threefold for every 10 °C rise, although real peptides do not always follow this neatly. This is the basis for cold storage.

Form	Common storage	Notes
Lyophilised, long term	−20 °C or below	Dry state minimises chemical reactions
Lyophilised, short term	2–8 °C	Acceptable for weeks for many peptides
Lyophilised, transit	Ambient for limited periods	Usually tolerated for days in dry form
In solution	2–8 °C short term, or aliquoted at −20 to −80 °C	Stability is sequence-dependent and much shorter than dry

Moisture

Water enables hydrolysis, deamidation and molecular mobility. Lyophilised peptides are hygroscopic, so a cold vial opened in humid air picks up condensation. Allowing the vial to reach room temperature before opening, and resealing promptly, protects the dry material.

Light

Ultraviolet and visible light can drive photo-oxidation, particularly of tryptophan, tyrosine and methionine, and can generate reactive oxygen species. Amber vials, foil wrapping and storage in the dark are simple precautions. ICH Q1B describes formal photostability testing for pharmaceuticals.

pH

pH controls which pathways dominate. Deamidation is faster at neutral and basic pH; Asp-Pro cleavage is faster in acid; disulfide exchange increases at basic pH. Many peptides are most stable in mildly acidic solution, which is one reason dilute acetic acid is a common solvent for basic peptides.

Freeze–thaw events

Freezing a peptide solution concentrates the peptide and any salts into small liquid pockets between ice crystals. Local pH can shift as buffer components crystallise, and ice surfaces can promote unfolding and aggregation. Each freeze–thaw event adds stress. The standard approach is to divide a reconstituted solution into single-use aliquots so each portion is thawed only once.

Detecting degradation

1. RP-HPLC shows new peaks, typically eluting just before (deamidated, oxidised) or after (some aggregates, hydrophobic adducts) the main peak.
2. Mass spectrometry identifies mass shifts such as +16 Da for oxidation or +1 Da for deamidation.
3. Size-exclusion chromatography detects dimers and larger aggregates.
4. Visual inspection reveals turbidity, particles or colour change, though many degradation products are invisible.

Short, simple sequences such as BPC-157 are generally robust in dry form, while longer, methionine-rich or aggregation-prone sequences require more care. When results drift over the course of a study, a fresh vial and a quick HPLC check against the original certificate can rule degradation in or out.

For practical handling after delivery, see reconstitution and storage of lyophilised peptides.

References

• Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6(11):903–918.
• Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575.
• Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. J Biol Chem. 1987;262(2):785–794.
• Robinson NE, Robinson AB. Molecular Clocks: Deamidation of Asparaginyl and Glutaminyl Residues in Peptides and Proteins. Althouse Press; 2004.
• Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490–500.
• Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129–188.
• International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. 2003.
• International Council for Harmonisation. ICH Q1B: Photostability Testing of New Drug Substances and Products. 1996.